Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin.

Gardner SF, Schneider EF, Granberry MC, Carter IR.

Pharmacotherapy. 1996 May-Jun;16(3):419-23.

PMID:
8726600
2.

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR; ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation.

Am J Cardiol. 2003 Mar 15;91(6):667-72.

PMID:
12633795
3.

Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.

Tsalamandris C, Panagiotopoulos S, Sinha A, Cooper ME, Jerums G.

J Cardiovasc Risk. 1994 Oct;1(3):231-9.

PMID:
7621303
4.

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.

Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.

Am J Cardiol. 2010 Feb 15;105(4):487-94. doi: 10.1016/j.amjcard.2009.10.001. Epub 2009 Nov 13.

PMID:
20152243
5.

Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.

Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.

Indian Heart J. 2008 May-Jun;60(3):215-22.

PMID:
19240310
6.
7.

A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.

Hunninghake DB, McGovern ME, Koren M, Brazg R, Murdock D, Weiss S, Pearson T.

Clin Cardiol. 2003 Mar;26(3):112-8.

8.

Niacin-based therapy for dyslipidemia: past evidence and future advances.

Ito MK.

Am J Manag Care. 2002 Sep;8(12 Suppl):S315-22. Review.

10.

Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.

Brown BG, Bardsley J, Poulin D, Hillger LA, Dowdy A, Maher VM, Zhao XQ, Albers JJ, Knopp RH.

Am J Cardiol. 1997 Jul 15;80(2):111-5.

PMID:
9230143
11.

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.

Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, Toth PD, Favrot LK, Kerzner B, Nash SD, Bays HE, Simmons PD.

Am J Cardiol. 2002 Mar 15;89(6):672-8.

PMID:
11897208
12.

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT.

N Engl J Med. 1990 Nov 8;323(19):1289-98.

13.

Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.

Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA.

Arch Intern Med. 1994 Jul 25;154(14):1586-95.

PMID:
8031206
14.

Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.

Malloy MJ, Kane JP, Kunitake ST, Tun P.

Ann Intern Med. 1987 Nov;107(5):616-23.

PMID:
3662275
15.

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.

Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.

J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. doi: 10.1016/j.jacc.2008.03.003.

16.

Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.

Zambón D, Ros E, Rodriguez-Villar C, Laguna JC, Vázquez M, Sanllehy C, Casals E, Sol JM, Hernández G.

Metabolism. 1999 Jan;48(1):47-54.

PMID:
9920144
18.

Niacin extended-release/lovastatin: combination therapy for lipid disorders.

Moon YS, Kashyap ML.

Expert Opin Pharmacother. 2002 Dec;3(12):1763-71. Review.

PMID:
12472373
19.

Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.

Insull W Jr, McGovern ME, Schrott H, Thompson P, Crouse JR, Zieve F, Corbelli J.

Arch Intern Med. 2004 May 24;164(10):1121-7.

PMID:
15159270
20.

Supplemental Content

Support Center